Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

About Us

Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.

read more

Vator Securities acts as Sole Global Coordinator and Bookrunner in Alligator Bioscience 151 MSEK Rights Issue

Alligator is a clinical-stage research and development-based biotechnology company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-directed immunotherapies, specifically agonistic mono- and bispecific antibodies. Immunotherapy is a type of treatment that stimulates the patient’s own immune system to cure cancer.

Alligator is active in the drug development phases ranging from concept and early drug discovery up to and including Phase 2 clinical studies involving patients. This includes the development and optimization of novel drug candidates, evaluation of preclinical efficacy and safety, and finally confirmatory clinical studies in cancer patients.

read more

Vator Securities advises Fenix Family in Capital Raise

Fenix ​​Family’s digital B2B2C service enables customers of banks and asset managers to estate plan in a simple, fast, and safe way. This means that, based on a will, Fenix ​​draws up a unique life plan for the end customer, their family, assets, and any loans. The plan includes legal agreements, tips on financial services and practical preparations for the family to have peace of mind here and now as well as in the future.

The company’s subscribers have grown strongly since launch. Growth is driven by the security Fenix ​​creates for end consumers and partners’ needs to digitalize and personalize an increasingly important aspect of financial services: estate planning.

read more

Vator Securities advises Chordate Medical on 42 MSEK Rights Issue

Chordate Medical is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis.

The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region.

read more

Vator Securities advises InCoax Networks on 53 MSEK Rights Issue

InCoax Networks re-purposes existing property coaxial networks in fiber and fixed wireless access (FWA) extension deployments for Communication Service Providers (CSP) globally.

The technology is a high performance, future proof, reliable and cost-effective complement, that reduces installation time and improves take-up rate, to boost digital inclusion and Internet access for all. 

read more

More News